Literature DB >> 15468278

The reporting quality of abstracts of randomised controlled trials submitted to the ICS meeting in Heidelberg.

Peter Herbison1.   

Abstract

AIMS: The quality of randomised controlled trials (RCTs) is associated with bias. Thus, reports of RCTs must have enough detail of key elements of quality to enable them to be interpreted properly. This study examines the quality of abstracts of RCTs reported at the ICS meeting in Heidelberg in 2002, using the CONSORT statement as the gold standard.
MATERIALS AND METHODS: All of the abstracts accepted for the meeting at Heidelberg were read to identify reports of RCTs. Copies of these were printed and examined to see whether they complied with the 22 items in the CONSORT statement. As these were all abstracts the first CONSORT item was changed so that to comply the title had to say it was a randomised trial. Each item was scored as not met, partially met, met.
RESULTS: Fifty-three reports of RCTs were found. Five of these were podium presentations, 14 discussion posters, and 34 non-discussion posters. Most reports did not comply with many of the items in the CONSORT statement, lacking particularly in technical details of the methods (only one study clearly reported hidden allocation to groups), and how the results were presented (only two studies fully reported results). Only 2/53 of the abstracts complied fully with more than 10 of the items, and 30/53 did not comply at all with 10 or more.
CONCLUSIONS: The quality of reporting of studies at ICS is so poor that it is difficult to interpret the results. Reporting was particularly poor on the details of the randomisation and the numeric results.

Mesh:

Year:  2005        PMID: 15468278     DOI: 10.1002/nau.20076

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  4 in total

1.  High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies.

Authors:  Tim Ellis-Caleo; Aaron Lisberg; D Andrew Tucker; Edward B Garon
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

2.  CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration.

Authors:  Sally Hopewell; Mike Clarke; David Moher; Elizabeth Wager; Philippa Middleton; Douglas G Altman; Kenneth F Schulz
Journal:  PLoS Med       Date:  2008-01-22       Impact factor: 11.069

Review 3.  Abstracts in high profile journals often fail to report harm.

Authors:  Enrique Bernal-Delgado; Elliot S Fisher
Journal:  BMC Med Res Methodol       Date:  2008-03-27       Impact factor: 4.615

Review 4.  Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.

Authors:  Shanthi Sivendran; Kristina Newport; Michael Horst; Adam Albert; Matthew D Galsky
Journal:  Trials       Date:  2015-08-08       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.